| Trial ID: | L7122 |
| Source ID: | NCT00726505
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Renal Mechanism of Action/Splay vs. TmG
|
| Acronym: |
MOA
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes, NOS
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: The change in urinary glucose excretion dynamics, after 7 days of treatment | Secondary: Differences in urinary glucose between healthy and diabetic subjects, at 7 days|Changes in liver glucose production, at one day|Glucose effects on tubular markers, at one day
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Bristol-Myers Squibb
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
1
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2009-06
|
| Completion Date: |
2009-08
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-17
|
| Locations: |
University Of Texas Health Center At San Antonio, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00726505
|
